Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1918 1
1948 1
1963 2
1964 1
1968 1
1970 1
1973 2
1974 2
1975 3
1976 4
1977 12
1978 6
1979 9
1980 6
1981 4
1982 7
1983 6
1984 14
1985 6
1986 8
1987 8
1988 9
1989 8
1990 5
1991 8
1992 12
1993 10
1994 21
1995 18
1996 31
1997 26
1998 24
1999 46
2000 60
2001 49
2002 46
2003 58
2004 65
2005 103
2006 98
2007 104
2008 87
2009 102
2010 109
2011 103
2012 121
2013 121
2014 142
2015 157
2016 132
2017 112
2018 115
2019 126
2020 157
2021 155
2022 162
2023 156
2024 191
2025 238
2026 174

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,257 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean asomotor symptoms menopause (1 results)?
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Lederman S, et al. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. Lancet. 2023. PMID: 36924778 Clinical Trial.
BACKGROUND: Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy. Fezolinetant is one of the first …
BACKGROUND: Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in …
The Menopause Transition: Signs, Symptoms, and Management Options.
Santoro N, Roeca C, Peters BA, Neal-Perry G. Santoro N, et al. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1-15. doi: 10.1210/clinem/dgaa764. J Clin Endocrinol Metab. 2021. PMID: 33095879 Free article. Review.
EVIDENCE SYNTHESIS: The reproductive hormonal milieu of the menopausal transition precipitates bothersome vasomotor symptoms, mood disruption, temporary cognitive dysfunction, genitourinary symptoms, and other disease processes that reduce the quality …
EVIDENCE SYNTHESIS: The reproductive hormonal milieu of the menopausal transition precipitates bothersome vasomotor symptom …
Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages.
Deecher DC, Dorries K. Deecher DC, et al. Arch Womens Ment Health. 2007;10(6):247-57. doi: 10.1007/s00737-007-0209-5. Epub 2007 Dec 12. Arch Womens Ment Health. 2007. PMID: 18074100 Review.
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are the menopausal symptoms for which women seek treatment during menopause most often. ...Hormone therapy is the most effective treatment for VMS and other …
Vasomotor symptoms (VMS), commonly called hot flashes or flushes (HFs) and night sweats, are the menopausal symptoms …
Menopause transition: Physiology and symptoms.
Talaulikar V. Talaulikar V. Best Pract Res Clin Obstet Gynaecol. 2022 May;81:3-7. doi: 10.1016/j.bpobgyn.2022.03.003. Epub 2022 Mar 16. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35382992 Review.
Every woman's experience of the menopausal transition is unique, and a one-size-fits-all approach to the management of symptoms does not work. An understanding of the pathophysiology and severity of menopausal symptoms and the benefits and risks associ …
Every woman's experience of the menopausal transition is unique, and a one-size-fits-all approach to the management of symptoms …
Management of Menopausal Symptoms: A Review.
Crandall CJ, Mehta JM, Manson JE. Crandall CJ, et al. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. JAMA. 2023. PMID: 36749328 Review.
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]). ...CONCLUSIONS AND RELEVA …
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symp …
The impact of physical activity and exercise interventions on symptoms for women experiencing menopause: overview of reviews.
Money A, MacKenzie A, Norman G, Eost-Telling C, Harris D, McDermott J, Todd C. Money A, et al. BMC Womens Health. 2024 Jul 13;24(1):399. doi: 10.1186/s12905-024-03243-4. BMC Womens Health. 2024. PMID: 39003439 Free PMC article. Review.
BACKGROUND: Women experiencing problematic menopausal symptoms report lower health-related quality of life and greater healthcare use than women without symptoms. ...There is evidence showing improvement of physical, urogenital, and total symptoms foll …
BACKGROUND: Women experiencing problematic menopausal symptoms report lower health-related quality of life and greater healthc …
Management of perimenopausal and menopausal symptoms.
Duralde ER, Sobel TH, Manson JE. Duralde ER, et al. BMJ. 2023 Aug 8;382:e072612. doi: 10.1136/bmj-2022-072612. BMJ. 2023. PMID: 37553173 Review.
Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and genitourinary sympto …
Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor …
Menopausal Symptoms and Their Management.
Santoro N, Epperson CN, Mathews SB. Santoro N, et al. Endocrinol Metab Clin North Am. 2015 Sep;44(3):497-515. doi: 10.1016/j.ecl.2015.05.001. Endocrinol Metab Clin North Am. 2015. PMID: 26316239 Free PMC article. Review.
Vasomotor symptoms are the most commonly reported, but vaginal dryness/dyspareunia, sleep difficulties and adverse mood changes have all been shown to worsen as women approach menopause. ...This article thus reviews the epidemiology, pathophysiology, diagn …
Vasomotor symptoms are the most commonly reported, but vaginal dryness/dyspareunia, sleep difficulties and adverse mood change …
Onset of the Menopause Transition: The Earliest Signs and Symptoms.
Gracia CR, Freeman EW. Gracia CR, et al. Obstet Gynecol Clin North Am. 2018 Dec;45(4):585-597. doi: 10.1016/j.ogc.2018.07.002. Epub 2018 Oct 25. Obstet Gynecol Clin North Am. 2018. PMID: 30401544 Review.
Although more than 80% of women experience some degree of psychological or physical symptoms around menopause, both women and clinicians have misconceptions about how hormonal changes relate to menopausal symptoms and psychological conditions. Recently …
Although more than 80% of women experience some degree of psychological or physical symptoms around menopause, both women and …
Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, Leite M, Morbach V, Alves Kelly F, Barros Í, Aquino de Moraes FC, Prevedello A. Menegaz de Almeida A, et al. Obstet Gynecol. 2025 Mar 1;145(3):253-261. doi: 10.1097/AOG.0000000000005812. Epub 2025 Jan 2. Obstet Gynecol. 2025. PMID: 39746208
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomot …
The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor s …
3,257 results